The days of simply determining the market demand for a new drug as a function of price and choosing the revenue or profit optimizing point are gone. In our new environment, an explicit rationale, the “value-based price” has become a prerequisite for enabling conversation with payers while policy-makers seem poised to limit the pricing corridors … Continued
在欧洲的真实世界数据源中，法国医疗保健数据库 SNDS 是最大、也可能是最全面的医疗保健数据资源，覆盖约 6500 万人的生活，超过 99% 的法国人口和约 10% 的欧洲人口。Watch this short video by Nadia Quignot, Director, Decision Analytics & Real World Evidence at … Continued
在欧洲的真实世界数据源中，法国医疗保健数据库 SNDS 是最大、也可能是最全面的医疗保健数据资源，覆盖约 6500 万人的生活，超过 99% 的法国人口和约 10% 的欧洲人口。In this short video by Nadia Quignot, Director, Decision Analytics & Real World Evidence at … Continued
在欧洲的真实世界数据源中，法国医疗保健数据库 SNDS 是最大、也可能是最全面的医疗保健数据资源，覆盖约 6500 万人的生活，超过 99% 的法国人口和约 10% 的欧洲人口。Watch this short clip by Nadia Quignot, Director, Decision Analytics & Real World Evidence at … Continued
在欧洲的真实世界数据源中，法国医疗保健数据库 SNDS 是最大、也可能是最全面的医疗保健数据资源，覆盖约 6500 万人的生活，超过 99% 的法国人口和约 10% 的欧洲人口。Watch this short video by Nadia Quignot, Director, Decision Analytics & Real World Evidence at … Continued
Watch this presentation to learn • Overview of the SNDS and the key working practices to access the database and ongoing SNDS developments • Similarities and differences between SNDS and other claims databases • Strengths and opportunities for HTAs and market access in Europe through case studies • Stakeholder perspectives: current and potential benefits to … Continued
Authors: Joseph McGuirk, Clint Divine, Seung Hyun Moon, Aastha Chandak, Zhiji Zhang, Genovefa A. Papanicolaou Hemorrhagic cystitis (HC) caused by viral infections such as BK virus, cytomegalovirus, and/or adenovirus after allogeneic hematopoietic stem cell transplantation (allo-HCT) causes morbidity and mortality, affects quality of life, and poses a substantial burden to the health care system. At … Continued
BY ROMAN CASCIANO, OPINION CONTRIBUTOR — 03/29/21 05:30 PM EDT No one is happy with the price of drugs nor how we pay for them: not patients, not the lawmakers who represent them, not physicians, not insurance payers and not drug developers. We are at a point where all stakeholders are fed up, and there’s (…)
